Drug Development Pipeline
Tobramycin Inhaled Powder (TOBI® Podhaler™)
The TOBI® Podhaler™ is the powder form of the inhaled antibiotic tobramycin and is used to treat people with CF who have Pseudomonas aeruginosa. It is taken with an inhaler, making it a convenient alternative to TOBI®, which must be taken using a nebulizer.
The TOBI Podhaler received FDA approval in March 2013 for people with CF.
The program is sponsored by Novartis Pharmaceuticals and supported by the Cystic Fibrosis Foundation. The trial was conducted within the Therapeutics Development Network.
Recent Tobramycin Inhaled Powder (TOBI® Podhaler™) Studies
Completed with Results
Latest News on Tobramycin Inhaled Powder
March 25, 2013
The U.S. Food and Drug Administration (FDA) has approved TOBI® Podhaler™ (tobramycin inhalation powder), a dry powder formulation of the antibiotic TOBI, to treat lung infections caused by the bacteria Pseudomonas aeruginosa (P. aeruginosa).
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More